The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis. Here we show that VEGFR2 is acetylated in endothelial cells both at four lysine residues forming a dense cluster in the kinase insert domain and at a single lysine located in the receptor activation loop. These modifications are under dynamic control of the acetyltransferase p300 and two deacetylases HDAC5 and HDAC6. We demonstrate that VEGFR2 acetylation essentially regulates receptor phosphorylation. In particular, VEGFR2 acetylation significantly alters the kinetics of receptor phosphorylation after ligand binding, allowing receptor phosphorylation and intracellular signaling upon prolonged stimulation with VEGF. Molecular dynamics simulations indicate that acetylation of the lysine in the activation loop contributes to the transition to an open active state, in which tyrosine phosphorylation is favored by better exposure of the kinase target residues. These findings indicate that post-translational modification by acetylation is a critical mechanism that directly affects VEGFR2 function.
Introduction
The activity of various members of the vascular endothelial growth factor (VEGF) family is essential for blood vessel formation and endothelial cell function (Adams and Alitalo, 2007; Carmeliet and Jain, 2011) . In mammals, five distinct, secreted, dimeric glycoproteins belong to this family and bind in an overlapping pattern to three different receptor tyrosine kinases (RTKs), namely VEGFR1, VEGFR2, and VEGFR3. The VEGF-A gene generates different protein isoforms, of which VEGF-A 165 is the most potent pro-angiogenic factor (Giacca, 2010) . Most VEGF-A-mediated downstream signaling ensues upon VEGFR2 activation, eventually resulting in endothelial cell differentiation, proliferation, migration, survival, and formation of the vascular tube (Olsson et al., 2006) . After ligand binding, the receptor undergoes dimerization and trans-autophosphorylation. At least six VEGFR2 tyrosine residues were found to be modified in response to VEGF stimulation: Tyr951 and Tyr996 located in the kinase insert region, Tyr1054 and Tyr1059 within the kinase insert domain (KID), and Tyr1175 and Tyr1214 that reside in the carboxy-terminal tail. Phosphorylation of these tyrosine residues creates binding sites for downstream effectors, thus leading to the initiation of different intracellular signal transduction cascades (Koch et al., 2011) .
Given the essential role of VEGFR2 in vascular development, it does not appear surprising that the functions of this receptor are finely tuned. At the protein level, this occurs through the regulation of both intracellular trafficking and compartmentalization (Lampugnani et al., 2006; Lanahan et al., 2010) , as well as by posttranslational modification (PTM) of the mature protein. Besides phosphorylation, receptor glycosylation is required for proper maturation and membrane presentation (Takahashi and Shibuya, 1997) , while Cbl-mediated ubiquitination routes the receptor for degradation (Shaik et al., 2012) .
Among the most prominent PTMs, lysine acetylation has emerged in the last decade as a crucial modification that regulates both nuclear and cytoplasmic processes by targeting a variety of non-histone proteins (Zhao et al., 2010) . This modification is dynamically controlled by two different types of enzymes, lysine acetyltransferases (KATs), which add the acetyl moiety on the 1-aminogroup of lysines, and lysine deacetylases (KDACs), which conversely remove the acetyl group (Lee and Workman, 2007; Yang and Seto, 2008b) . Regulation of protein function by acetylation is of particular interest, since it has been frequently linked to other PTMs, most notably phosphorylation. A growing body of evidence now supports the existence of a crosstalk among various PTMs, a sort of 'protein modification code' responsible for the final regulation of protein function (Yang and Seto, 2008a) .
By combining biochemical and proteomics studies, here we provide the first evidence that acetylation also regulates activity of VEGFR2. In particular, we report that VEGFR2 is acetylated in endothelial cells at five highly conserved lysines located in the intracellular portion of the receptor. This modification is under dynamic control of the acetyltransferase p300 and two deacetylases HDAC5 and HDAC6. We show that VEGFR2 acetylation positively regulates receptor phosphorylation and maintains receptor activity upon prolonged ligand stimulation.
Results

Ligand-dependent acetylation of VEGFR2 in endothelial cells
We observed that VEGFR2 is modified by acetylation in endothelial cells. We immunoprecipitated the receptor from primary human umbilical vein endothelial cells (HUVECs) and then probed the immunoprecipitated proteins with an antibody specific for acetylmodified lysines. Cell treatment with the class I/II histone deacetylases inhibitor trichostatin A (TSA) strongly increased acetylation of the receptor ( Figure 1A) . In HUVEC lysates immunoprecipitated with an anti-acetyl-lysine antibody, VEGFR2 was the only VEGF receptor showing a marked increase upon cell treatment with TSA (Supplementary Figure S1A) . Endogenous receptor acetylation was also observed in porcine aortic endothelial cells stably expressing human VEGFR2 (PAE/KDR) ( Figure 1B ) (Waltenberger et al., 1994) .
The lysine acetyl-transferase (KAT) responsible for VEGFR2 acetylation was identified by testing the members of two main classes of KATs, namely p300 from the p300/CBP family and GCN5 and P/CAF from the GNAT family (Lee and Workman, 2007) . After overexpression of these KATs in PAE/KDR cells, we found that p300 was the only enzyme effective at catalyzing VEGFR2 acetylation ( Figure 1C) . To further confirm that the enzymatic activity of p300 was directly required for VEGFR2 acetylation, we measured the level of receptor acetylation in PAE/KDR cells expressing the enzymatically inactive mutant p300-DY, carrying an inactivating, single-amino acid substitution (Ito et al., 2001; Sabo et al., 2008) . This mutant was ineffective at inducing VEGFR2 acetylation ( Figure 1D ). The acetylation of VEGFR2 is not cell type-specific as these findings were reproduced in HEK293T cells co-transfected with VEGFR2 in combination with p300, GCN5, or P/CAF (Supplementary Figure S1B) . The VEGFR2 acetylation levels decreased upon treatment with LysCoA, a synthetic inhibitor of p300 enzymatic activity (Lau et al., 2000; Cereseto et al., 2005) (Supplementary Figure S1C) .
The levels of phosphorylation and acetylation of endogenous VEGFR2 in HUVECs in response to VEGF stimulation were also evaluated. Similar to the reported literature, phosphorylation of the receptor was undetectable in serum-starved cells, while it peaked at 5 min following addition of rhVEGF and decreased at later times ( Figure 2A) . The kinetics of receptor acetylation was slightly delayed relative to phosphorylation, starting to be detectable at 5 min and peaking at 15 min after rhVEGF addition (quantified in Figure 2B ). We also found that VEGFR2 and p300 physically interacted in HUVECs by immunoprecipitating the endogenous receptor and then probing the immunoprecipitates with an antibody specific for p300; TSA treatment did not affect this interaction ( Figure 2C ). The association of p300 with the receptor was induced by stimulation with rhVEGF, as the co-immunoprecipitation of the acetyltransferase with the receptor increased as early as 5 min after addition of the growth factor, peaked at 15 min, and decreased at later time points, thus mirroring the kinetics of VEGFR2 acetylation ( Figure 2D) .
No appreciable modification in p300 localization was detected upon rhVEGF stimulation; at all time points, a fraction of p300 was found in the cytoplasm, with the vast majority being inside the nucleus (Supplementary Figure S2) .
Collectively, these results indicate that endogenous VEGFR2 is modified by reversible acetylation following VEGF stimulation in endothelial cells and that p300 is the acetyltransferase responsible for this modification.
Deacetylation of VEGFR2 by KDACs
Since lysine acetylation is a reversible modification, and considering that VEGFR2 acetylation is transitory following rhVEGF stimulation, we investigated which deacetylase recognizes the receptor as a substrate. First, we tested the inhibitors of different KDAC classes on the level of VEGFR2 acetylation. In HUVECs, the inhibition of neither class III (sirtuins) by nicotinamide (NAM) nor class I (KDACs) by the specific inhibitor MS275 (entinostat) (Hu et al., 2003) increased endogenous VEGFR2 acetylation ( Figure 3A and B) . Conversely, increased acetylation was detected in cells treated with the class II-specific inhibitor MC1575 (Mai et al., 2003) (Figure 3B) . Thus, we focused on the Class II enzymes. Coimmunoprecipitation experiments revealed that HDAC5 and HDAC6, but not HDAC4, HDAC7, or HDAC9, interacted with VEGFR2 ( Figure 3C ). Consistent with these findings, we also observed that overexpression of HDAC5 and HDAC6 in PAE/KDR cells significantly decreased the levels of endogenous VEGFR2 acetylation ( Figure 3D) .
Finally, we wondered what was the kinetics of association of HDAC5 and HDAC6 with VEGFR2 upon receptor activation. In the absence of rhVEGF, low amounts of both HDACs were found bound to the receptor. Addition of the ligand stimulated this interaction, which peaked at 15 min for HDAC5 while remained constantly high for HDAC6 (representative blots in Figure 3E and quantifications in Figure 3F and G). In the presence of HDAC6, both endogenously expressed and transfected p300 showed less ability to interact with the receptor (Supplementary Figure S3A and B, respectively). Consistently, in HUVECs where HDAC6 was silenced, co-immunoprecipitation of p300 with VEGFR2 was markedly increased (Supplementary Figure S3C) . Thus, HDAC6 and p300 appear to compete for binding to VEGFR2.
Together, these results indicate that acetylation of VEGFR2 is reversed by its association with histone deacetylases in a liganddependent manner.
Identification of the lysines acetylated in VEGFR2
We immunoprecipitated VEGFR2 from HEK293T cells and recovered two bands from an SDS-PAGE gel, the higher of 250 kDa and the lower of 220 kDa, corresponding to fully and partially glycosylated VEGFR2, respectively. Both bands were analyzed by MALDI-TOF/TOF mass spectrometry.
Five of the 38 lysines present in the VEGFR2 intracellular portion were detected as acetylated from three independent experiments (Supplementary Table S1 and Figure S4 ). These were Lys929, Lys937, Lys939, Lys947, and Lys1053 (corresponding to Lys931, 939, 941, 949, and 1055 of human VEGFR2, respectively; Figure 4A and B). The intracellular portion of VEGFR2 consists of the kinase domain, which is split into two parts by the KID. Four of the residues that were acetylated (Lys929, Lys937, Lys939, and Lys947) form a cluster in the KID. They are located near a wellcharacterized tyrosine, Tyr949 (human Tyr951), which was shown to be phosphorylated and to mediate TSAd-dependent cell signaling (Matsumoto et al., 2005) .
The fifth acetylated residue, Lys1053, is positioned in the activation loop of the receptor, within the second kinase domain. Intriguingly, this acetylated lysine is flanked by two critical autophosphorylation sites (Tyr1052 and Tyr1057 in the mouse sequence), which are required for maximal VEGFR2 kinase activity (Dougher and Terman, 1999) . All the acetylated lysines are highly conserved between human, mouse, and rat; both Lys929 and Lys1053 are also maintained in mouse VEGFR1 and VEGFR3 ( Figure 4B ).
We constructed mutants of the full-length mouse VEGFR2 carrying substitutions of lysines with arginines, which conserve the positive charge, but cannot be acetylated. Three mutants were generated: M1 that is mutated in the lysine located in the activation loop only (Lys1053Arg), M4 mutated in the four lysines clustered in the KID (Lys929,937,939,947Arg), and M5 mutated in all five lysines detected as acetylated ( Figure 4C ). After transfection in HEK293T cells and TSA treatment, acetylation of all three mutants was significantly reduced, in particular that of M4 and M5 (representative experiment and quantification in Figure 4D and E, respectively).
To further confirm this observation, we also tested VEGFR2 acetylation in vitro. We produced His-tagged recombinant proteins corresponding to the wild type (wt) and mutated (M1, M4, and M5) intracellular domain of mouse VEGFR2 (aa 805-1356). Wt VEGFR2 incubated with the recombinant HAT domain of p300 fused to GST scored clearly positive for acetylation in the presence of 14 C acetyl-CoA, whereas the acetylation of mutants M4 and M5 appeared significantly impaired (representative experiment and quantification in Figure 4F and G, respectively). In addition to VEGFR2, the HAT domain of p300 was also acetylated due to the autocatalytic activity of the enzyme.
These results indicate that at least five lysine residues are acetylated in VEGFR2, which are located in the intracellular portion of the receptor and are conserved among species.
VEGFR2 acetylation does not affect protein stability
Since VEGFR2 undergoes lysine ubiquitination (Shaik et al., 2012) , and lysine acetylation is known to impact on protein stability by interplaying with this modification (Caron et al., 2005; Xiong and Guan, 2012) , we first assessed whether acetylation modifies stability of the receptor. We compared the decay of VEGFR2 in HUVECs, upon de novo protein synthesis inhibition with cycloheximide (CHX), in normal conditions, or after treatment with TSA. No difference in the kinetics of VEGFR2 degradation was observed (Supplementary Figure S5A and B). A similar experiment was performed in PAE cells that lack endogenous VEGFR2 and the Neuropilin-1 co-receptor, which were transfected to express wt or M5 VEGFR2. Again, no difference between the two proteins was observed (Supplementary Figure S5C and D) . We conclude that VEGFR2 acetylation does not regulate receptor stability. 
Acetylation regulates VEGFR2 phosphorylation
Since acetylation is known to modulate phosphorylation of other proteins (Tang et al., 2007; Yang and Seto, 2008a; Sundaresan et al., 2011) and given the proximity of the acetylated lysines to main VEGFR2 autophosphorylation sites, we investigated whether acetylation of VEGFR2 influences its phosphorylation. We transfected PAE/KDR cells with wt p300 or p300-DY; after rhVEGF stimulation, VEGFR2 was immunoprecipitated from the whole cell lysate (WCL) and probed with an anti-phospho-tyrosine antibody. In p300-overexpressing cells, the magnitude of VEGF-induced receptor phosphorylation was markedly increased. In contrast, in cells transfected with p300-DY, rhVEGF stimulation was almost ineffective, consistent with a dominant negative effect. Both p300 and p300-DY co-immunoprecipitated with VEGFR2, irrespective of rhVEGF stimulation (blots in Figure 5A and quantification in Figure 5B ).
To gain insight into the role of different acetylated lysine residues in tyrosine phosphorylation, we assessed the levels of VEGF-induced phosphorylation of VEGFR2 mutants in PAE cells. VEGFR2 phosphorylation was analyzed in WCL using antibodies specific for phospho-Tyr1173 (human Tyr1175), an essential residue in VEGF-induced signal transduction (Sakurai et al., 2005) . The mutant, non-acetylated variants of the receptor, especially the M4 and M5 mutants, were less phosphorylated compared with the wt protein (see Figure 5C for representative blots and Figure 5D for the quantification).
Since it is the fully glycosylated form of the receptor, expressed on the cell surface, that undergoes phosphorylation (Takahashi and Shibuya, 1997) , we also performed the same experiment by selectively labeling the cell surface molecules with activated biotin followed by recovery of biotinylated proteins by streptavidin beads. VEGFR2 phosphorylation was analyzed again using the antibody specific for phospho-Tyr1173 and also an antibody recognizing phospho-Tyr1052 (human Tyr1054), a critical autophosphorylation site located in the activation loop (Dougher and Terman, 1999) . We found that the M4 and M5 mutants showed a significant decrease in VEGF-induced phosphorylation on Tyr1173 ( Figure 5E and F) . On the other hand, phosphorylation of Tyr1052 was significantly reduced in mutants M1 and M5, which carries lysine to arginine substitution at the adjacent residue 1053, while it was similar to wt in mutant M4 (blots and quantification in Figure 5G and H, respectively). Finally, we performed an in vitro kinase assay incubating the recombinant VEGFR2 proteins with the Poly (Glu2Tyr) peptide as a substrate. The receptor kinase activity was comparable between wt and M1 VEGFR2, whereas only an 25% decrease was observed in the case of the M4 and M5 mutants ( Figure 5I ). This finding rules out that the major impairment observed for mutant receptor phosphorylation might be consequent to an intrinsically decreased kinase activity.
Collectively, these data suggest that p300-mediated VEGFR2 acetylation markedly enhances its autophosphorylation in response to ligand stimulation. 
Structural modeling of the VEGFR2 activation loop
We used structural modeling to get insights into the role of Lys1053 acetylation on the conformation of the activation loop. An exhaustive search of the Protein Data Bank (www.pdb.org) revealed that, among the 38 structures reported for VEGFR2 in complex with different inhibitors, only seven contain the complete structure of the activation loop in its unphosphorylated form. Notably, in all these X-ray structures (PDB ids: 4AGD, 4AGC, 4AG8, 3U6J, 3VHK, 4ASE, and 3VNT), Lys1053 is completely exposed to the solvent (Supplementary Figure S6) and one or both of the tyrosines present in the activation loop (Tyr1052 and Tyr1057) are completely buried. Therefore, we sought to perform molecular dynamics simulations starting from the structure of VEGFR2 phosphorylated at Tyr1052 and Tyr1057 and in complex with a benzimidazole inhibitor (PDB id: 2OH4, Figure 6A ) (Hasegawa et al., 2007) . Simulations were performed removing the inhibitor for the following systems: wt VEGFR2 kinase domain phosphorylated at Tyr1052 and 1057 ( Figure 6B) ; wt VEGFR2 kinase domain unphosphorylated ( Figure 6C) ; wt VEGFR2 kinase domain phosphorylated at Tyr1052, 1057 and acetylated at Lys1053 ( Figure 6D) ; wt VEGFR2 kinase domain acetylated at Lys1053 ( Figure 6E) ; and VEGFR2 kinase domain Lys1053Arg mutant ( Figure 6F) .
Analysis of these computational models revealed that the removal of the phosphoryl groups from Tyr1052 and Tyr1057 resulted in a reduction of the solvent accessible surface (SAS) of the phosphorylation motif, most likely due to a reduction of the electrostatic repulsion ( Figure 6G and Supplementary Video S1). This result is in agreement with the more compact conformation obtained from X-ray crystallography for the activation loop in its unphosphorylated form (Oguro et al., 2010) , in which Lys1053 is partially buried inside the middle of the activation loop, flanked by Tyr1052 and Tyr1057 ( Figure 6A and C) . Lysine acetylation of the unphosphorylated protein resulted in a more exposed conformation of the activation loop, in which the flanking tyrosine residues were uncovered and thus accessible for phosphorylation (Figure 6E and Supplementary Video S2). Significantly, acetylation at Lys1053 of the phosphorylated protein did not affect the structure (Figure 6B , D, G, and Supplementary Video S3). Furthermore, modeling the mutation of Lys1053 into arginine generated a compact conformation, similar to that of the unphosphorylated protein ( Figure 6F ). This structure was the least flexible, since the entire activation loop was stabilized by a network of hydrogen bonds ( Figure 6F , inset, and Supplementary Video S4). Thus, the impediment in the exposure of the tyrosines would determine an environment less favorable to their phosphorylation.
Taken together, these results provide a structural context to explain the increased levels of VEGF-induced VEGFR2 phosphorylation imparted by acetylation and, more specifically, the remarkable reduction in levels of Tyr1052 phosphorylation in the Lys1053Arg mutant.
Acetylation prevents VEGFR2 desensitization and enhances its function
Different RTKs, including VEGFR2, undergo receptor dephosphorylation as a mean of desensitization after activation (Nakamura et al., 2008; Lanahan et al., 2010) . We therefore assessed the possible role of acetylation in modifying the kinetics of VEGFR2 phosphorylation after VEGF-induced activation. PAE/KDR cells were treated with rhVEGF and, at different times after stimulation, the levels of VEGFR2 phosphorylation at Tyr1173 and Tyr1052 were analyzed. In control conditions, the levels of phosphorylated VEGFR2 at both residues peaked at 5 min, sharply decreased by 15 min, and remained very low in the subsequent 2 h. In contrast, in the cells treated with TSA, phosphorylation was higher after 5 min of stimulation and, most notably, maintained over time ( Figure 7A for a representative experiment and Figure 7B and C for quantification). The increased levels of phosphorylated VEGFR2 in TSA-treated cells were paralleled by increased phosphorylation of ERK1/2, a pivotal downstream effector of the receptor ( Figure 7D) . The same experiment was performed comparing the kinetics of receptor activation in PAE cells stably expressing wt or M5 VEGFR2. Consistent with the previous observations, the mutant was remarkably impaired in VEGF-induced phosphorylation at Tyr1173 ( Figure 7E and F) . The same results were reproduced in PAE cells transiently expressing wt or M5 VEGFR2 (Supplementary Figure S7A and B for representative images and quantification, respectively). Moreover, in cells stably expressing the M5 mutant, activation of VEGFR2 downstream signaling, including ERK1/2, p38, and AKT phosphorylation, was impaired ( Figure 7E for representative blots and Figure 7G2I for quantification).
To assess the functional significance of VEGFR2 acetylation, we monitored the response of PAE cells transiently expressing wt or M5 VEGFR2 in a wound-healing assay upon rhVEGF stimulation. Phase-contrast images were taken immediately after the creation of the wound (t ¼ 0) and 24 h after rhVEGF stimulation (t ¼ 24); the migration rate of endothelial cells was determined after quantification of the wound size at fixed time points (Supplementary Figure S8A) . In wt VEGFR2-expressing cells, VEGF treatment for 24 h induced cell motility to fill the wounded monolayer; this effect was clearly impaired in cells expressing mutant M5, which failed to respond to VEGF stimulation ( Figure 8A and B for representative images and quantification, respectively). Wt VEGFR2 and mutant M5 were equally expressed in the PAE cells (Supplementary Figure S8B) .
Expression of VEGFR2 M5 also impaired endothelial cell sprouting. PAE cells stably expressing the mutant receptor, when coated onto microcarrier beads and embedded into a fibrin gel, showed significantly reduced sprout length in response to rhVEGF compared with cells expressing wt VEGFR2 ( Figure 8C and D) . Finally, proliferation of stable clones expressing the M5 mutant was significantly reduced compared with clones expressing the wt receptor, as assessed by EdU incorporation (Supplementary Figure S9) .
Together, these data support the conclusion that VEGFR2 acetylation contrasts receptor desensitization, counteracting its dephosphorylation and hence enhancing its activity.
Discussion
By mass spectrometry analysis, we found several acetylation sites in murine VEGFR2, mainly located in the intracellular part of the receptor. In particular, the peptides encompassing Lys929, Lys937, Lys939, Lys947, and Lys1053 were identified for several times in three independent experiments. Notably, all these residues are conserved in mouse, human, and rat, suggesting their relevance in regulating receptor function. Lysines at positions 929 -947 form a dense cluster in the KID. Interestingly, acetylation has also been found to cluster in other proteins where groups of lysine residues form positively charged patches (Zhang et al., 2007; Goh et al., 2010) . In contrast to the 9292947 lysine cluster, lysine 1053 is not surrounded by other acetylated lysines. Instead, this lysine is located in the middle of the VEGFR2 activation loop, near two critical autophosphorylation sites (Tyr 1052 and Tyr 1057) (Dougher and Terman, 1999) . Both regions appear to conform to the general residue preferences in the proximity of the acetylated sites, as detected by various computational studies indicating that acetylation preferentially occurs in regions with ordered secondary structure, with a widespread preference for lysine-rich regions containing a residue that can be phosphorylated, and with a particular predilection for negative charge residues in the immediate surrounding of the modified site (Choudhary et al., 2009; Lundby et al., 2012) .
Being the VEGF-induced VEGFR2 phosphorylation significantly increased by acetylation, VEGFR2 joins the growing list of proteins in which lysine acetylation regulates enzymatic activity, including Cdk2, Cdk9, and p38 (Sabo et al., 2008; Mateo et al., 2009; Pillai et al., 2011) . In particular, computational modeling of the VEGFR2 activation loop indicates that acetylation of lysine 1053, by quenching the positive charge of the residue, aids in the transition of the activation loop toward a more open state, in which the two tyrosine residues 1052 and 1057 are better exposed on the surface of the protein and become accessible for phosphorylation. Mutation of lysine 1053 into arginine, instead, generated a less flexible system, in which the entire activation loop was partially buried and stabilized by a network of hydrogen bonds. The structural modeling is corroborated by the observation that the nonacetylable VEGFR2 mutants show impaired auto-phosphorylation capability. More specifically, the lack of acetylation at lysine 1053 correlated with a decrement in the phosphorylation at tyrosine 1052, an effect that our in vitro phosphorylation studies showed to be not consequent to an intrinsic loss of receptor tyrosine kinase activity in the absence of ligand following residue substitution. Mutational data on VEGFR1 and VEGFR2 have already indicated that mutation of an invariable, negatively charged aspartic acid to non-polar asparagine at position 1054 lowers the autophosphorylation of activation loop tyrosines 1052 and 1057; the presence of this same asparagine in VEGFR1 might explain the poor autophosphorylation and signal transduction activity of this receptor in endothelial cells (Meyer et al., 2006) .
The acetylation occurring in lysine-rich regions has been widely hypothesized to lead to protein conformational shift, as in the case of p300 and p53 (Kawaguchi et al., 2006; Arif et al., 2007) . Unfortunately, we were not able to provide a molecular modeling of the region surrounding the 9292947 lysine cluster, since so far the high electrostatic charge and hydrophilicity of the KID sequence did not render the crystallization of the VEGFR2 catalytic domain with the entire KID sequence possible (Hasegawa et al., 2007) . Nevertheless, we could not exclude that a mechanism of acetylation-induced conformational change, similar to that observed in the VEGFR2 activation loop, might affect several VEGFR2 catalytic residues, in particular tyrosine 1173.
P300 is responsible for VEGFR2 acetylation in both endothelial and non-endothelial cells. Besides its well-established function as a transcriptional co-activator, p300 is known to shuttle in and out of the nucleus and to act in the cytoplasm (Tang et al., 2007; Shi et al., 2009) . Previous work indicates that the depletion of p300 significantly reduces angiogenic tubule formation (Pillai et al., 2010) . This report is fully consistent with our findings, in particular with the experiments showing that the receptor mutated in the lysines that undergo p300-mediated acetylation has impaired ability to induce endothelial cell migration in response to VEGF.
Increasing evidence indicates the contribution of class IIa KDACs, such as HDAC5, HDAC6, and HDAC7, to the angiogenic function of endothelial cells (Wang et al., 2008; Urbich et al., 2009; Kaluza et al., 2011) . In particular, HDAC6 has already been shown to promote angiogenesis in vitro and in vivo by deacetylating the cytoplasmic actin-remodeling protein cortactin in endothelial cells, thereby regulating endothelial cell migration and sprouting (Kaluza et al., 2011) . We found that specific inhibition of class II KDACs markedly increased the level of acetylation of VEGFR2; both HDAC5 and HDAC6 interacted with the receptor in a VEGF-dependent manner.
Contrary to what happens to the CBP subcellular distribution upon IFNa or EGF treatment (Tang et al., 2007; Song et al., 2011) , we did not observe any variation in p300 localization in endothelial cells consequent to VEGF stimulation. Nevertheless, the formation of a complex between VEGFR2 and p300 was VEGF-dependent, and correlated with an increment of receptor acetylation. At this time point, the activity of the histone deacetylases associated with the receptor prevails, with the subsequent, progressive deacetylation of the receptor. An interplay between p300 and both HDAC5 and HDAC6 was also reported in other settings. In particular, HDAC5 was described to stimulate association of p300 with one of its substrates, HIF1a (Seo et al., 2009) . Since, in our experiments, p300 and HDAC5 associate with VEGFR2 with similar kinetics, it is tempting to speculate that HDAC5 might perform similarly also in this case. Besides, p300 was involved in the attenuation of HDAC6 activity, by directly interacting with and acetylating this class II histone deacetylase (Han et al., 2009; Liu et al., 2012) . Additionally, HDAC6 was shown to block the interaction between p53 and p300, interfering with p300-mediated p53 acetylation (Ding et al., 2013) . Our data show that HDAC6 negatively affects the interaction of VEGFR2 with p300, keeping with the kinetics of receptor deacetylation after VEGF stimulation. Consistent with the kinetic data of association with the receptor, the inhibition of KDAC activity preserves receptor phosphorylation over time after ligand stimulation and maintains its capacity to transduce intracellular signals. Thus, it can be concluded that, upon VEGF stimulation, protein acetylation counteracts receptor desensitization and thus contributes to the maintenance of VEGFR2 phosphorylation. Besides being broadly considered as potent anticancer reagents for their global effects on chromatin structure, histone deacetylase inhibitors (KDACi) are also regarded as negative regulators of angiogenesis (Kwon et al., 2002; Qian et al., 2006; Ellis et al., 2009) . The apparent contradiction between the use of KDACi to inhibit tumor angiogenesis and our novel findings linking VEGFR2 hyperacetylation with increased receptor activation might be partially explained by the fact that prolonged deacetylases inhibition has a major impact on gene expression, rather than on the fine tuning of VEGFR2 activity. Consistent with this consideration, the expression of VEGFR2 itself was reported to decrease in response to long-term treatment with KDACi (Deroanne et al., 2002; Kwon et al., 2002) . In this respect, a challenging issue would be to understand at what extent the acetylation-dependent upregulated activity of VEGFR2 might be responsible for the relatively poor efficacy of KDACi monotherapy, which is rescued by the combination with a VEGFR tyrosine kinase inhibitor (Qian et al., 2004; Thurn et al., 2011; Qiu et al., 2013) .
Taken together, our findings support the conclusion that VEGFR2 acetylation favors and sustains receptor activation in endothelial cells, and reinforces the concept that a strict crosstalk exists between PTM by acetylation and other PTMs (Yang and Seto, 2008a) . Whether this novel mechanism of regulation of receptor function also applies more generally to RTK family members remains a matter for future investigation.
Materials and methods
Plasmids and cells
Description of plasmids and conditions for cell culture and treatments are reported in the Supplementary material.
Antibodies
Anti-VEGFR2, anti-VEGFR3, anti-HA, anti-HDAC5 and HDAC6, and anti-p300 antibodies were purchased from Santa Cruz. Anti-Flag and anti-tubulin were from Sigma. Anti-total acetyl-lysine, antiphospho-VEGFR2 1173, anti-phospho-ERK1/2, anti-ERK, antiphospho-AKT, anti-AKT, anti-phospho-p38, and anti-p38 antibodies were from Cell Signaling Technology; anti-VEGFR1 was from Abcam; anti-phospho-VEGFR2 1054, clone D1W, was purchased from Millipore; anti-total phospho-tyrosine, clone 4G10, was from Upstate. Conditions for western blotting, immunoprecipitation, and immunofluorescence are reported in the Supplementary material.
Cell surface biotinylation assay
Cells were treated for 30 min on ice with 0.5 mg/ml of thiolcleavable Sulfo-NHS-S-S-Biotin (Pierce, Thermo Scientific) in ice-cold PBS containing Ca 2+ and Mg 2+ . Unreacted biotin was quenched with ice-cold H/S buffer (25 mM HEPES, pH 7.4 and 150 mM NaCl). After cell lysis with ice-cold biotinylation lysis buffer, equal amounts of proteins from each sample were incubated with Streptavidin agarose resins (Pierce, Thermo Scientific).
In vitro acetylation assay
HAT assays were performed as previously reported (Cereseto et al., 2005) .
In vitro kinase assay
In vitro VEGFR2 kinase activity was assayed by ELISA. 500 ng of His-VEGFR2 recombinant protein were incubated with 20 mM ATP and 6 mM Poly (Glu-Tyr) Biotinylated Peptide (Cell Signaling) at room temperature for 30 min. Samples were then transferred to a 96-well streptavidin-coated plate (Thermo Scientific) to allow binding of the biotinylated peptide to streptavidin. Substrate phosphorylation was monitored using a colorimetric ELISA detection assay.
Computational modeling
Molecular dynamics simulations were performed using the generalized Born model approach for implicit solvation as implemented in the AMBER package (Tsui and Case, 2000) . A time step of 2 fs and a cutoff of 1.8 nm was adopted. All systems were stabilized by 0.2 ns, during which the temperature was linearly raised from 0 to 300K coupling the systems to a Langevin thermostat with a collision frequency of 2/picosecond (Loncharich et al., 1992) . Subsequently, 25 ns of production runs were performed for all the simulated systems. The SAS, reported in Figure 5G , was calculated on residues Asp1050 to Ala1063.
Wound-healing assay
Confluent monolayers of PAE cells transiently expressing wt or M5 VEGFR2 were mechanically scratched to create a cell-free zone and then stimulated with rhVEGF for 24 h. To block cell proliferation, 0.25 mM thymidine was added to the medium. Phase-contrast images were taken immediately after the scratch (time 0) and 24 h later; the scratched areas were imaged at both time points using a DM IL LED microscope (Leica). The wound area was determined using the Volocity 5.5 software (Perkin Elmer). Endothelial cell migration was calculated by subtracting the wound area at time 24 h with that at time 0.
Sprouting assay
Microcarrier beads (Cytodex 3; Sigma) coated with PAE cells stably expressing wt or M5 VEGFR2 were added to a solution of bovine fibrinogen (2.5 mg/ml; Sigma) and aprotinin (4U/ml; Sigma) in 24-well plates. Thrombin (0.625 U/ml; Sigma) was used to induce the fibrinogen clotting. After 30 min incubation at 378C, DMEM/F12 medium, supplemented with rhVEGF, and human fibroblasts (2 × 10 4 per well) were added to each well. Sprouts were fixed in paraformaldehyde 4% after 24 h. Sprout length was measured on phase-contrast images using the Volocity 5.5 software (Perkin Elmer).
Additional materials and methods
Additional experimental protocols are presented in the Supplementary material.
Supplementary material
Supplementary material is available at Journal of Molecular Cell Biology online.
